Vir Biotechnology (VIR) Interest Coverage Ratio (2018 - 2026)
Vir Biotechnology (VIR) reported Interest Coverage Ratio of 193.12 for Q1 2026, up 94.05% on a YoY basis from 99.52 in Q1 2025, and up 91.94% sequentially from 2396.05 in Q4 2025.
Vir Biotechnology (VIR) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 9 years of Interest Coverage Ratio data on file, last reported at 193.12 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 94.05% year-over-year to 193.12; the trailing twelve-month figure through Mar 2026 stood at 689.15 (up 95.42% YoY), and the FY2025 full-year result was 0.91, up 29.78% from the prior year.
- Interest Coverage Ratio grew to 193.12 in Q1 2026, from 2396.05 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 5.5 in Q1 2022 to a low of 8566.81 in Q3 2024.
- A 5-year average of 1644.69 and a median of 156.24 in 2023 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio soared 1104.94% in 2022 and plunged 927219.41% in 2025, its largest moves.
- Tracing VIR's Interest Coverage Ratio over 5 years: stood at 0.74 in 2022, then surged by 47.04% to 0.39 in 2023, then jumped by 33.68% to 0.26 in 2024, then plunged by 927219.41% to 2396.05 in 2025, then soared by 91.94% to 193.12 in 2026.
- Business Quant data shows VIR's Interest Coverage Ratio at 193.12 in Q1 2026, 2396.05 in Q4 2025, and 2588.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | -193.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -193.12 |
| Dec 31, 2025 | -2,396.05 |
| Sep 30, 2025 | -2,588.70 |
| Jun 30, 2025 | -2,234.28 |
| Mar 31, 2025 | -3,245.28 |
| Dec 31, 2024 | -0.26 |
| Sep 30, 2024 | -8,566.81 |
| Jun 30, 2024 | -127.41 |
| Mar 31, 2024 | -6,673.42 |
| Dec 31, 2023 | -0.39 |
| Sep 30, 2023 | -185.07 |
| Jun 30, 2023 | -108.79 |
| Dec 31, 2022 | -0.74 |
| Sep 30, 2022 | 1.09 |
| Jun 30, 2022 | -1.23 |
| Mar 31, 2022 | 5.50 |
| Dec 31, 2021 | 12.51 |
| Sep 30, 2021 | -0.29 |
| Jun 30, 2021 | 0.27 |
| Mar 31, 2021 | -0.55 |